NCT02338375 (Cartistem) is a EARLY_PHASE1 clinical trial of Cartistem in Osteochondral Lesion of Talus, sponsored by Samsung Medical Center.

Who is sponsoring NCT02338375?

NCT02338375 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT02338375?

Interventions in NCT02338375: Cartistem.

What condition does NCT02338375 study?

NCT02338375 studies Osteochondral Lesion of Talus.

Is NCT02338375 still recruiting?

NCT02338375 is currently status unknown. Last updated 11 January 2015.

Last reviewed 2015-01-11 · How we verify

NCT02338375: Cartistem

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients

Status unknown EARLY_PHASE1 Last updated 11 January 2015

What this trial tests

EARLY_PHASE1 trial testing Cartistem in Osteochondral Lesion of Talus in 28 participants. Status unknown.

Timeline

1 December 2012

Primary endpoint
1 August 2015

1 December 2015

Quick facts

Lead sponsor	Samsung Medical Center
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	28
Start date	1 December 2012
Primary completion	1 August 2015
Estimated completion	1 December 2015
Sites	1 location across South Korea

Drugs / interventions tested

Cartistem — full drug profile →

Conditions studied

Osteochondral Lesion of Talus — all drugs for Osteochondral Lesion of Talus →

Sponsor

Samsung Medical Center

Who can join

Adults 20 to 70, any sex, with Osteochondral Lesion of Talus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) on currently standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A systematic review of the concept and clinical applications of Bone Marrow Aspirate Concentrate in Orthopaedics.
Imam MA, Mahmoud SSS, Holton J, Abouelmaati D, et al · · 2017 · cited 33× · PMID 29792397 · DOI 10.1051/sicotj/2017007

Verify or expand the search:

Other recruiting trials for Osteochondral Lesion of Talus

Currently open trials in the same condition.

NCT06358807 — Microfracture With Platelet Rich Plasma Gel Injection for Osteochondral Lesion of the Talus · NA · recruiting
NCT06527482 — Autologous Osteoperiosteal Transplantation for the Treatment of Severe Osteochondral Lesions of the Talus · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02338375 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 11 January 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02338375.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing